News
AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback